We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

456 hedge funds and large institutions have $6.17B invested in Bio-Rad Laboratories Class A in 2024 Q4 according to their latest regulatory filings, with 81 funds opening new positions, 148 increasing their positions, 147 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 56

32% more call options, than puts

Call options by funds: $5.22M | Put options by funds: $3.94M

4% more funds holding

Funds holding: 437456 (+19)

1% more repeat investments, than reductions

Existing positions increased: 148 | Existing positions reduced: 147

3.24% less ownership

Funds ownership: 85.21%81.97% (-3.2%)

5% less capital invested

Capital invested by funds: $6.5B → $6.17B (-$329M)

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

Holders
456
Holders Change
+19
Holders Change %
+4.35%
% of All Funds
6.01%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
81
Increased
148
Reduced
147
Closed
56
Calls
$5.22M
Puts
$3.94M
Net Calls
+$1.28M
Net Calls Change
-$631K
Name Holding Trade Value Shares
Change
Change in
Stake
FRM
201
Fox Run Management
Connecticut
$1.03M +$1.06M +3,122 New
Mirae Asset Global Investments
202
Mirae Asset Global Investments
South Korea
$1.01M -$101K -297 -9%
Nomura Holdings
203
Nomura Holdings
Japan
$1M +$1.04M +3,055 New
WAM
204
Westport Asset Management
Connecticut
$986K
PS
205
Principal Securities
Iowa
$984K +$953K +2,807 +1,501%
Mariner
206
Mariner
Kansas
$974K +$8.49K +25 +0.9%
DT
207
Diversified Trust
Tennessee
$958K +$990K +2,916 New
Neuberger Berman Group
208
Neuberger Berman Group
New York
$952K +$2.04K +6 +0.2%
Pacer Advisors
209
Pacer Advisors
Pennsylvania
$914K -$10.2K -30 -1%
OAM
210
Oppenheimer Asset Management
New York
$892K +$15.3K +45 +2%
AI
211
Atria Investments
North Carolina
$846K -$23.8K -70 -3%
MWM
212
Moran Wealth Management
Florida
$798K +$27.2K +80 +3%
NAM
213
Nissay Asset Management
Japan
$792K -$29.5K -87 -4%
Pathstone Holdings
214
Pathstone Holdings
New Jersey
$782K +$43.8K +129 +6%
VPIM
215
Vanguard Personalized Indexing Management
California
$780K +$177K +522 +28%
VOYA Investment Management
216
VOYA Investment Management
Georgia
$755K -$73K -215 -9%
PAS
217
Park Avenue Securities
New York
$753K +$171K +504 +28%
KBC Group
218
KBC Group
Belgium
$749K -$276K -814 -26%
Marshall Wace
219
Marshall Wace
United Kingdom
$749K +$774K +2,279 New
ETC
220
Exchange Traded Concepts
Oklahoma
$743K -$3.39K -10 -0.4%
Corient Private Wealth
221
Corient Private Wealth
Florida
$726K -$153K -452 -17%
SOADOR
222
State of Alaska Department of Revenue
Alaska
$722K -$8.49K -25 -1%
Creative Planning
223
Creative Planning
Kansas
$716K +$186K +549 +34%
M&T Bank
224
M&T Bank
New York
$716K +$67.9K +200 +10%
BCP
225
Blackhawk Capital Partners
Wisconsin
$715K +$484K +1,427 +191%

BIO Hedge Fund Activity: Q4 2024 in Review

456 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2024, worth a combined $6.17B — down 5.1% from $6.5B a quarter earlier.

Buyers outnumbered sellers: 81 funds opened new BIO positions and 56 closed out — a net gain of 25 holders — while 148 added to existing stakes and 147 trimmed.

The largest buyer was Ariel Investments, adding an estimated $61.7M. The largest seller was VanEck Associates, cutting an estimated $197M.

  • 456 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2024, up from 437 in Q3 2024.
  • Funds reported $6.17B of Bio-Rad Laboratories Class A stock for Q4 2024, down 5.1% quarter-over-quarter.
  • 81 funds opened new Bio-Rad Laboratories Class A positions in Q4 2024 and 56 closed out, a net change of +25 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q4 2024 was Ariel Investments, an estimated $61.7M added.
  • The largest Bio-Rad Laboratories Class A seller in Q4 2024 was VanEck Associates, an estimated $197M sold.

Based on aggregated 13F filings for Q4 2024.